Windward Bio Debuts on Nasdaq, Shares Jump 68% at Close
Clinical-stage biotech Windward Bio priced its IPO at $17 and closed at $28.50 on its first trading day on Nasdaq.
Windward Bio, a clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, under the ticker symbol WWB, the company announced from its Shanghai headquarters.
The company priced its initial public offering at $17.00 per share, but investor demand pushed the stock significantly higher on the first day of trading. Shares closed at $28.50, representing a gain of roughly 68 percent from the IPO price — a strong opening for a biotech in the immunology space.
Read more Exchange Traded Concepts to Liquidate TSLA Income ETF TYYY →
Windward Bio operates as a portfolio company of Qiming Venture Partners, a prominent venture capital firm with deep roots in Asian technology and life sciences investment. The Nasdaq listing marks a significant milestone for the firm and signals continued appetite among public market investors for innovative immunology-focused drug developers.
The listing reflects broader trends in cross-border biotech capital raising, as China-linked clinical-stage companies continue to access U.S. equity markets to fund research and development pipelines. Windward Bio's strong first-day performance suggests institutional and retail investors alike see promise in its immunology platform, though clinical-stage biotechs carry inherent pipeline risk ahead of regulatory milestones.
Continue reading at All Financial Services & Investing.